Effectiveness of pharmacy interventions in improving availability of essential medicines at the primary healthcare level

Tropical Medicine and International Health

Volumn 16, Issue 5, 2011, Pages 647-658

  Nunan, Michael ^a   Duke, Trevor ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF PAPUA NEW GUINEA   (Papua New Guinea)

Author keywords

Developing countries; Drugs; Essential; Health services accessibility; Pharmaceutical services; Public sector

Indexed keywords

AMOXICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; CARDIOVASCULAR AGENT; COTRIMOXAZOLE; ERYTHROMYCIN; ETHAMBUTOL; ISONIAZID; MISOPROSTOL; MORPHINE; NIFEDIPINE; PARACETAMOL; PENICILLIN G; PROPRANOLOL; PYRAZINAMIDE; RETINOL; RIFAMPICIN; ZINC SULFATE;

DEVELOPING WORLD; DRUG; HEALTH POLICY; HEALTH SERVICES; INCENTIVE; LITERATURE REVIEW; PUBLIC HEALTH; PUBLIC SECTOR; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

EMBASE; HEALTH CARE AVAILABILITY; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; LOWEST INCOME GROUP; MEDICAL LITERATURE; MEDLINE; MIDDLE INCOME GROUP; PRIMARY MEDICAL CARE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SOCIAL STATUS; STAFF TRAINING; SYSTEMATIC REVIEW;

DEVELOPING COUNTRIES; DRUGS, ESSENTIAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; PHARMACEUTICAL SERVICES; PRIMARY HEALTH CARE; PUBLIC SECTOR;

EID: 79954976096     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2011.02748.x     Document Type: Review

References (34)

1. Ahmad K (2002) Access denied to essential medicines in developing world. The Lancet Infectious Diseases 2, 711.
2. Akashi H, Yamada T, Huot E, Kanal K & Sugimoto T (2004) User fees at a public hospital in Cambodia: effects on hospital performance and provider attitudes. Social Science & Medicine 58, 553.
3. Andersson S & Snell B (2010) Where There Are No Pharmacists, 1st edn. TWN and Health Action International Asia Pacific, Penang, Malaysia.
4. Babar ZD & Izham MI (2009) Effect of privatization of the drug distribution system on drug prices in Malaysia. Public health 123, 523-533.
5. Babar ZU, Ibrahim MI, Singh H, Bukahri NI & Creese A (2007) Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Medicine/Public Library of Science 4, e82.
6. Bennet S, Quick JD & Velasquez G (1997) Public-private roles in the pharmaceutical sector: implications for equitable access and rational drug use. WHO Action Programme on Essential Drugs (DAP), Geneva, WHO/DAP97.12.
7. Cameron A, Ewen M, Ross-Degnan D, Ball D & Laing R (2009) Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373, 240-249.
8. Carasso BS, Lagarde M, Tesfaye A & Palmer N (2009) Availability of essential medicines in Ethiopia: an efficiency-equity trade-off? Tropical Medicine & International Health 14, 1394-1400.
9. Chaudhury RR, Parameswar R, Gupta U, Sharma S, Tekur U & Bapna JS (2005) Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. Health Policy and Planning 20, 124-136.
10. Duke T (2004) Inequity in child health: what are the sustainable pacific solutions? Medical Journal of Australia 181(11-12), 612-614.
11. England R (2007) The dangers of disease specific aid programmes. The British Medical Journal 335, 565.
12. Harries AD, Schouten EJ, Makombe SD et al. (2007) Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi. Bulletin of the World Health Organization 85, 152-155.
13. Jagwe JGM & Merriman A (2007) Uganda: delivering analgesia in rural Africa: opioid availability and nurse prescribing. Journal of Pain & Symptom Management 33, 547.
14. Kisinza WN, Kisoka WJ, Mutalemwa PP et al. (2008) Community directed interventions for malaria, tuberculosis and vitamin A in onchocerciasis endemic districts of Tanzania. Tanzania journal of health research 10, 232-239.
15. Kotwani A, Ewen M, Dey D et al. (2007) Prices & availability of common medicines at six sites in India using a standard methodology. Indian Journal of Medical Research 125, 645.
16. Management Sciences for Health, Euro Health Group (1997) Managing Drug Supply, 2nd edn. Kumarian Press, West Hartford, CT.
17. Mendis S, Fukino K, Cameron A et al. (2007) The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bulletin of the World Health Organization 85, 279-288.
18. Murakami H, Phommasack B, Oula R & Sinxomphou S (2001) Revolving drug funds at front-line health facilities in Vientiane, Lao PDR. Health Policy & Planning 16, 98.
19. Mwabu G, Mwanzia J & Liambila W (1995) User charges in government health facilities in Kenya: effect on attendance and revenue. Health Policy & Planning 10, 164-170.
20. National Department of Health (2003) Operational Plan for Comprehensive HIV and AIDS Care, Management and Treatment for South Africa. Pretoria, South Africa.
21. Quick JD (2003) Essential medicines twenty-five years on: closing the access gap. Health Policy & Planning 18, 1-3.
22. Saleh K & Ibrahim MI (2005) Are essential medicines in Malaysia accessible, affordable and available? Pharmacy World & Science 27, 442-446.
23. Special Programme for Research & Training in Tropical Diseases (2008) Community-directed Interventions for Major Health Problems in Africa: A Multi-country Study: Final Report. Geneva, Switzerland.
24. Steyn F, Schneider H, Engelbrecht MC, van Rensburg-Bonthuyzen EJ, Jacobs N & van Rensburg DH (2009) Scaling up access to antiretroviral drugs in a middle-income country: public sector drug delivery in the free state, South Africa. AIDS Care 21, 1-6.
25. Summers RS, Moller H, Meyer D & Botha R (1998) "Contracting-out" drug procurement and distribution: experience with a primary distributor system in South Africa. Essential Drugs Monitor, 25-26.
26. Trap B, Todd CH, Moore H & Laing R (2001) The impact of supervision on stock management and adherence to treatment guidelines: a randomized controlled trial. Health Policy & Planning 16, 273-280.
27. Turshen M (2001) Reprivatizing pharmaceutical supplies in Africa. Journal of public health policy 22, 198-225.
28. Umenai T & Narula I (1999) Revolving drug funds: a step towards health security. Bulletin of the World Health Organization 77, 167-171.
29. USAID: DELIVER Project (2009) After Receiving USAID/DELIVER Project Logistics Training, Access to Health Products Improces in Nepal. Newsbrief, July, 2009. Accessed on April 7, 2010 at.
30. Uzochukwu BSC, Onwujekwe OE & Akpala CO (2002) Effect of the Bamako-initiative drug revolving fund on availability and rational use of essential drugs in primary health care facilities in south-east Nigeria. Health Policy and Planning 17, 378-383.
31. World Bank (2010) World Bank: Countries and Economies [Homepage of The World Bank Group], [Online]. Available at: [2010, 09/30].
32. World Health Organisation Maximising Positive Synergies Collaborative Group (2009) An assessment of interactions between global health initiatives and country health systems. The Lancet 373, 2137.
33. World Health Organisation, Regional Office for Africa (2004) Management of Drugs at Health Centre Level. WHO, South Africa.
34. Yu D, Souteyrand Banda M, Kaufman J & Perriens J (2008) Investment in HIV/AIDS programs: does it help strengthen health systems in developing countries? Globalization & Health 4, 8.